MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Histone deacetylase (HDAC) inhibitors are a promising class of anti-cancer agents.
• Trichostatin A (TSA), a known HDAC inhibitor, exhibits anti-cancer properties including cell cycle arrest and apoptosis induction.
• The precise molecular mechanisms of TSA's action require further elucidation.

Purpose of the Study:

• To investigate the molecular targets of TSA in colon cancer cells.
• To identify specific genes regulated by TSA treatment.
• To explore the role of minichromosome maintenance protein-2 (MCM-2) in TSA-mediated anti-cancer effects.

Main Methods:

• RT-PCR array analysis to screen cell cycle-associated genes in HCT116 cells treated with TSA.
• Quantitative RT-PCR and Western blotting to validate MCM-2 expression changes.
• Small interfering RNA (siRNA) to silence MCM-2 expression and assess its impact on cell cycle and apoptosis.
• Analysis of JNK phosphorylation in response to TSA treatment.

Main Results:

• TSA treatment significantly altered the expression of 34 out of 84 cell cycle-associated genes in HCT116 cells.
• MCM-2 gene expression was significantly downregulated by TSA, confirmed by multiple methods.
• Silencing MCM-2 using siRNA mimicked TSA's effects, inducing cell cycle arrest and apoptosis.
• TSA treatment increased phosphorylated JNK, which was implicated in the downregulation of MCM-2.

Conclusions:

• MCM-2 is a novel therapeutic target of TSA in colon cancer.
• TSA exerts its anti-cancer effects, at least in part, by downregulating MCM-2 expression via JNK signaling.
• Targeting MCM-2 represents a potential therapeutic strategy for colon cancer treatment with HDAC inhibitors like TSA.